Lv72
4920 积分 2021-07-09 加入
Prevalence and Treatment of Diabetes in China, 2013-2018
10天前
已完结
From lipids to glucose: Investigating the role of dyslipidemia in the risk of insulin resistance
11天前
已完结
Efficacy and safety of inclisiran in patients with and without type 2 diabetes mellitus: a subgroup analysis from the CHOLINET Registry
14天前
已完结
Achievement of Guideline-Recommended Targets in Diabetes Care in China
25天前
已完结
Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting
25天前
已完结
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
26天前
已完结
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
26天前
已完结
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
1个月前
已完结
Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024
1个月前
已完结
Prevalence and Treatment of Diabetes in China, 2013-2018
1个月前
已完结
皖公网安备34019202002308
